Topics
Kidney transplantation
Rejection
Transplantation outcomes
Conference Coverage
American Transplant Congress 2011
More...
Education
Highlights From the American Transplant Congress 2011
More...
Slidesets
Improving Long-term Outcomes in Renal Transplant Recipients: Balancing Immunosuppression and Toxicity
Highlights From the American Transplant Congress 2011
CCO Slideset: Highlights From the American Transplant Congress 2011
More...
Save Bookmark
Print
Email to a Colleague
CCO Home
/ Transplantation
Renal Transplantation
Philadelphia Transplant
Latest Content
10 of 17 Shown
Improving Long-term Outcomes in Renal Transplant Recipients: Balancing Immunosuppression and Toxicity
Expert faculty led by Flavio Vincenti, MD, and Donald Hricik, MD, present data on using maintenance immunosuppression regimens to best prolong graft survival and at the same time manage toxicity related to the regimens.
Source:
A Master Class in Improving Long-term Outcomes in Renal Transplant Recipients: Balancing Immunosuppression and Toxicity
Date Posted:
6/6/2012
Highlights From the American Transplant Congress 2011
In this downloadable slideset, Seth J. Karp, MD, and Flavio Vincenti, MD, provide commentary and analysis on key studies in transplantation from the 2011 American Transplant Congress.
Source:
American Transplant Congress 2011
Faculty:
Seth J. Karp MD, Flavio Vincenti MD
Released:
6/15/2011
CCO Slideset: Highlights From the American Transplant Congress 2011
In this downloadable slideset, Seth J. Karp, MD, and Flavio Vincenti, MD, review key studies in transplantation from the 2011 American Transplant Congress.
Source:
American Transplant Congress 2011
Date Posted:
5/19/2011
Alefacept-Based Regimens Significantly Reduce T-Cell Memory Subsets but Associated With Increased Rejection Rates vs Control Regimen in Kidney Transplant Recipients
Patients in alefacept arms more likely to not complete at least 6 months of therapy compared with control arm; higher rates of discontinuation largely driven by adverse events and graft rejection.
Source:
American Transplant Congress 2011
Date Posted:
5/5/2011
Total Lymphoid Irradiation, Antithymocyte Globulin, and Donor Hematopoietic Cell Infusion Safely and Successfully Induces Tolerance After HLA-Matched Kidney Transplant
Posttransplant conditioning regimen of total lymphoid irradiation, antithymocyte globulin, and donor hematopoietic cell infusion promoted safe development of mixed chimerism and tolerance in majority of HLA-matched kidney transplant recipients.
Source:
American Transplant Congress 2011
Date Posted:
5/5/2011
HIV-Related Factors Such as HIV-1 RNA and CD4+ Cell Count Not Associated With Survival After Kidney or Liver Transplantation in HIV-Infected Individuals
In this prospective cohort study, the strongest factors associated with survival among kidney recipients were hepatitis C virus coinfection and age, whereas dual organ transplantation, pretransplantation BMI, and donor age demonstrated the strongest survival associations in liver transplant recipients.
Source:
American Transplant Congress 2011
Date Posted:
5/5/2011
Proteasome Inhibitor–Based Therapy Provides Effective Reversal of Antibody-Mediated Rejection in Kidney Transplantation
Rates of histologic improvement, graft survival, and patient survival all high with bortezomib therapy with acceptable toxicity profile.
Source:
American Transplant Congress 2011
Date Posted:
5/5/2011
BENEFIT and BENEFIT-EXT: Pooled Safety Data Through 3 Years Reveal No New Safety Signals Associated With Belatacept Costimulation Blockade
The risk of PTLD with belatacept was highest during the first 18 months of treatment, and most cases occurred in EBV-negative patients.
Source:
American Transplant Congress 2011
Date Posted:
5/4/2011
Preliminary Results Suggest That Alemtuzumab Induction Followed by Belatacept and Sirolimus Maintenance Prevents Renal Allograft Rejection and Alloantibody Formation
This novel calcineurin inhibitor– and steroid-free regimen appears to have potential, although with the potential for asymptomatic BK viremia.
Source:
American Transplant Congress 2011
Date Posted:
5/4/2011
Favorable Graft and Patient Survival Among HIV-Infected Patients Who Received Kidney Transplant Regardless of Use of NIH Study Protocol or Center Experience
Excellent graft and patient survival observed among HIV-infected patients who received kidney transplant for ESRD, regardless of center experience with HIV-positive ESRD transplant patients or enrollment according to NIH study protocol.
Source:
American Transplant Congress 2011
Date Posted:
5/4/2011
10 of 17 Shown
Show 7 More
Loading...
Filter Content By
Topic:
All topics
Heart transplantation
Hepatitis C
HIV
Immunosuppression
Intestinal transplantation
Kidney transplantation
Novel agents
PTLD
Rejection
Transplantation outcomes
Subtopic:
All subtopics
Content type:
All content types
Animations
Audio
Capsule Summaries
ClinicalThought Discussions
Decision Tools
Interactive Cases
PDF
Slidesets
Text
Video
Virtual Presentations
Conference only:
Available for credit:
Credit type:
All credit types
AMA
ANCC
ACPE
AAPA
Languages:
All languages
Burmese
Cambodian
Chinese Simplified
Chinese Traditional
English
French
German
Hmong
Italian
Korean
Portuguese
Spanish
Tagalog
Vietnamese
Author:
All authors
CCO Live Meetings
There are currently no events open for registration. Please check back later.